CMND Latest Press Releases

-- October 27, 2026 --

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial Globe Newswire 8:22 AM

-- October 12, 2026 --

Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets Globe Newswire 7:55 AM

-- October 8, 2026 --

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder Globe Newswire 7:32 AM

-- October 7, 2026 --

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA Globe Newswire 8:40 AM

-- September 23, 2026 --

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations Globe Newswire 8:35 AM

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations Globe Newswire 7:57 AM

-- September 17, 2026 --

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. Globe Newswire 7:42 AM

-- September 11, 2026 --

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial Globe Newswire 8:00 AM

-- September 8, 2026 --

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results Globe Newswire 7:42 AM

-- September 4, 2026 --

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis Globe Newswire 7:32 AM

-- September 1, 2026 --

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled Globe Newswire 7:37 AM

-- August 24, 2026 --

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation Globe Newswire 8:51 AM

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation Globe Newswire 8:03 AM

-- August 13, 2026 --

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint Globe Newswire 7:36 AM

-- August 11, 2026 --

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery Globe Newswire 8:05 AM

-- August 6, 2026 --

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study Globe Newswire 8:00 AM

-- August 3, 2026 --

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company Globe Newswire 8:02 AM

-- July 30, 2026 --

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial Globe Newswire 8:30 AM

-- July 28, 2026 --

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial Globe Newswire 7:47 AM

-- July 20, 2026 --

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market Globe Newswire 7:55 AM

-- July 17, 2026 --

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction Globe Newswire 7:32 AM

-- July 16, 2026 --

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI Globe Newswire 9:30 AM

-- July 13, 2026 --

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial Globe Newswire 8:17 AM

-- July 10, 2026 --

Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative Globe Newswire 8:32 AM

-- July 7, 2026 --

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI Globe Newswire 7:42 AM

-- June 29, 2026 --

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength Globe Newswire 7:55 AM

-- June 22, 2026 --

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial Globe Newswire 8:07 AM

-- June 18, 2026 --

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators Globe Newswire 7:55 AM

-- June 16, 2026 --

Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial Globe Newswire 7:32 AM

-- June 5, 2026 --

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on "Inside MEAI" Webinar Globe Newswire 7:32 AM

-- May 29, 2026 --

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment Globe Newswire 8:32 AM